Amylyx Pharmaceuticals will no longer sell a drug for Lou Gehrig’s disease as it did not prove effective. Patients already taking the therapy can continue to receive it for free.
The maker of a drug for Lou Gehrig’s disease recently announced that it will pull the medicine from the market as it did not help patients with the condition. Amylyx Pharmaceuticals will halt sales and marketing of the drug in the U.
S. and Canada, and new patients will no longer be able to get a prescription. However, patients already taking the therapy can enroll in a program to receive it for free.
Drug Lou Gehrig’S Disease Amylyx Pharmaceuticals Market Patients Therapy
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Newly approved cancer drug targets aggressive form of ‘deadly disease’A new drug regimen for certain types of pancreatic cancer recently got approval from the FDA — the first new medication in nearly a decade. Physicians weigh in on what it means.
Baca lebih lajut »
Parkinson's Drug Reduces Disease Markers in Breakthrough TrialThe Best in Science News and Amazing Breakthroughs
Baca lebih lajut »
Families of children with rare, life-threatening disease push FDA to review drug applicationBarth Syndrome affects 130 known American men and boys. It occurs only in the male population and causes an enlarged heart and overall muscle weakness.
Baca lebih lajut »
FDA approves the first drug for life-threatening liver diseaseMadrigal Pharmaceuticals' new drug has become the first drug approved by the US FDA to treat NASH, a fatty liver disease.
Baca lebih lajut »
FDA Approves First Drug for Common, Serious Liver DiseaseMillions of Americans whose livers develop scar tissue due to a common disease now have the first approved drug, Rezdiffra, to treat the condition, the U.S. Food and Drug Administration announced Thursday.
Baca lebih lajut »
Healthy Returns: The first drug for a common, deadly liver disease is hereDrugmakers are racing to catch up to Madrigal Pharmaceuticals, which has the first drug for NASH liver disease. Meanwhile, AI takes center stage at HIMSS.
Baca lebih lajut »